Yumiko Hirokawa - Concepedia

Author

Yumiko Hirokawa

Walter and Eliza Hall Institute of Medical Research ORCID

Also Known As

Hirokawa, Y., Y Hirokawa, Y. Hirokawa, YUMIKO HIROKAWA, Yumiko Hirokawa

202

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Walter and Eliza Hall Institute of Medical Research The University of Melbourne Ludwig Cancer Research The Royal Melbourne Hospital Monash University

About

Yumiko Hirokawa is an author at Walter and Eliza Hall Institute of Medical Research specializing in medicine, cell biology, and cell signaling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	424
2	Natural Sciences	5	5	182
3	Health Sciences	3	3	133
4	Biochemistry	3	3	127
5	Biology	1	1	39

Yumiko Hirokawa

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Imbalance of the renin–angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target? Mayur Garg, Simon G. Royce, Chris Tikellis, Gut	2019	207
Wnt Signalling Pathway Parameters for Mammalian Cells Chin Wee Tan, Bruce S. Gardiner, Yumiko Hirokawa, PLoS ONE	2012	132
A Clue to the Therapy of Neurofibromatosis Type 2 Yumiko Hirokawa, Anjali Tikoo, John Huynh, The Cancer Journal	2004	101
Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance Yumiko Hirokawa, Melissa Wervey Arnold, Hidenori Nakajima, Cancer Biology & Therapy	2005	80
Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells Zilu Wang, Matteo Burigotto, Sabrina Ghetti, Cancer Discovery	2023	79
Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt–β-catenin–mediated intestinal tumor growth and regeneration Toby J. Phesse, Michael Büchert, Emma Stuart, Science Signaling	2014	75
Synthesis and Conformational Analysis of a Non-Amidine Factor Xa Inhibitor That Incorporates 5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-<i>c</i>]pyridine as S4 Binding Element Noriyasu Haginoya, Syozo Kobayashi, Satoshi Komoriya, Journal of Medicinal Chemistry Pharmaceutical ScienceBioorganic ChemistryX-ray Crystal AnalysisPharmacotherapyHeterocycle Chemistry	2004	70
The K252a Derivatives, Inhibitors for the PAK/MLK Kinase Family, Selectively Block the Growth of HAS Transformants Thao Nheu, Hong He, Yumiko Hirokawa, The Cancer Journal	2002	69
PAK Is Essential for RAS-Induced Upregulation of Cyclin D1 During the G1 to S Transition Thao Nheu, Hong He, Yumiko Hirokawa, Cell Cycle Molecular RegulationCyclin D1ImmunologyCell ProliferationCell Cycle	2004	64
Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. Hong He, Yumiko Hirokawa, Edward Manser, PubMed	2001	48

Page 1